How immuno-oncology M&A performed in the pharmaceutical industry in Q3 2023
In value terms, immuno-oncology-related deal activity decreased by 92% in Q3 2023 compared with the previous quarter’s total of $6.9bn and fell by 94% as compared to Q3 2022. Related deal volume decreased by 77% in Q3 2023 versus the previous quarter and was 60% lower than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Centerview Partners; Guggenheim Partners; HC Wainwright with 3, 2, 2 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Cooley; Goodwin Procter; Gibson, Dunn & Crutcher with 5, 5, 4 deals respectively.
For further understanding of GlobalData’s Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Source link
#immunooncology #performed #pharmaceutical #industry
